Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a comprehensive selection of premium anti-CEACAM5 antibodies tailored to meet the diverse needs of your research. Our antibodies are characterized by their outstanding specificity, sensitivity, and strong affinity for CEACAM5, making them ideal for various applications. We pride ourselves on our exceptional customer support team, which is ready to assist you with product recommendations, technical questions, and order management, ensuring that your research journey is as smooth and productive as possible.
CEACAM5, a cell surface glycoprotein frequently overexpressed in various cancers, has emerged as a potential therapeutic target. Its elevated expression is associated with tumor progression, invasion, and metastasis. By understanding the role of CEACAM5 in cancer biology, researchers are developing innovative strategies to disrupt its function such as antibody-based therapies, vaccines, small molecule inhibitors, etc. Continued research and development are essential to fully realize the potential of CEACAM5 as a therapeutic target and improve outcomes for cancer patients.
CEA Cell Adhesion Molecule 5; Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; Carcinoembryonic Antigen Related Cell Adhesion Molecule 5; Carcinoembryonic Antigen; CD66e; CD66e Antigen; Meconium Antigen 100.
This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. Additionally, the encoded protein may regulate differentiation, apoptosis, and cell polarity. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants.
Creative Biolabs excels in providing premium anti-CEACAM5 antibodies, engineered for exceptional accuracy and efficacy in scientific research. Our antibodies are carefully developed to ensure focused performance while minimizing cross-reactivity with other proteins. With a diverse range of customizable formats at your disposal, researchers can select the antibody that aligns perfectly with their specific experimental requirements, facilitating deeper and more meaningful scientific discoveries.
Table 1. Featured anti-CEACAM5 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-408LC | Anti-Human CEACAM5 Recombinant Antibody (A5B7) | Human | Mouse | WB, ELISA, etc. |
MOB-1138z | Mouse Anti-CEACAM5 Recombinant Antibody (clone 32B10) | Human | Mouse IgG1, κ | WB, IP, IF, FC |
TAB-428LC | Anti-Human CEACAM5 Recombinant Antibody (COL-Human 10) | Human | Mouse | FC, WB |
TAB-416LC | Human Anti-CEACAM5 Recombinant Antibody | Human | Human IgG1 | ELISA, FC, Inhib |
TAB-703 | Anti-Human CEACAM5 Recombinant Antibody (Altumomab) | Human | Mouse | IF, IP, Neut, FuncS, ELISA, FC, IHC, etc. |
Creative Biolabs is committed to offering researchers a diverse selection of premium anti-CEACAM5 antibodies. Each antibody undergoes rigorous testing to ensure it adheres to top-quality standards and achieves optimal performance across various applications. Our unwavering focus on quality ensures that our products comply with the highest industry benchmarks, delivering reliable and consistent results that support the advancement of your scientific research.
Fig.1 SDS-PAGE analysis of anti-CEACAM5 antibody
(Cat# TAB-408LC, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CEACAM5 antibody
(Cat# TAB-408LC, Creative Biolabs).
Fig.3 WB analysis of anti-CEACAM5 antibody
(Cat# TAB-408LC, Creative Biolabs).
Fig.4 ELISA analysis of anti-CEACAM5 antibody
(Cat# TAB-408LC, Creative Biolabs).
Creative Biolabs harnesses a cutting-edge recombinant antibody platform that employs innovative genetic engineering techniques to produce premium anti-CEACAM5 antibodies. This groundbreaking method facilitates efficient and adaptable antibody production, guaranteeing a consistent supply of antibodies customized to fulfill the varied needs of researchers across multiple applications.
Featured Anti-CEACAM5 Recombinant Antibody Production Platforms
Fig.5 Milligram-scale anti-CEACAM5 recombinant antibody production.
Fig.6 Gram-scale anti-CEACAM5 recombinant antibody production.
Creative Biolabs provides an extensive array of top-notch anti-CEACAM5 recombinant antibodies with diverse formats, designed to cater to your unique research requirements with flexibility and precision.
Fig.7 Full-length anti-CEACAM5 recombinant antibody production and modalities.
Table 2. Public drug targeting CEACAM5.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Pre-Registered | Anti-CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; CD66e) | Monoclonal Antibodies | Hybritech (Originator) | |
Phase III | Drugs Targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA; CD66e) |
Chimeric Monoclonal Antibodies Fluorescence Imaging Agents |
Cancer, colon Cancer, colorectal Cancer, colorectal, metastatic Cancer, metastatic (to brain) Cancer, metastatic (to lung) Cancer, pancreas Cancer, rectum Digestive-gastrointestinal cancer |
Institut Regional du Cancer Montpellier (Originator) Institut Regional du Cancer Montpellier SurgiMab (Originator) |
Phase III |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers HER2 (erbB2)-Directed Immunity Inducers Melanoma-Associated Antigen 3 (MAGEA3; MAGE-3)-Directed Immunity Inducers Signal Transduction Modulators |
Cancer Immunotherapy Cancer Vaccines Peptides Peptide Vaccines |
Cancer, colorectal Cancer, lung Cancer, lung (non-small cell) (NSCLC) Cancer, ovary Cancer, pancreas Cancer, pancreas (ductal adenocarcinoma) |
Chong Kun Dang Bio Epimmune (Takeda) IDM (Takeda) OSE Immunotherapeutics Ose Pharma (OSE Immunotherapeutics) Rafa Laboratories Takeda (Originator) |
Phase III | Anti-CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; CD66e) |
Anti-Idiotype Vaccines Cancer Immunotherapy Cancer Vaccines Murine Monoclonal Antibodies |
Cancer, colorectal Cancer, colorectal, metastatic Cancer, lung (non-small cell) (NSCLC) |
National Cancer Institute Titan (Originator) |
Phase II |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers Mucin-1 (MUC1)-Directed Immunity Inducers |
Adenoviral Vectors Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Lynch syndrome |
ImmunityBio (Originator) National Cancer Institute |
Phase II |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers Mucin-16 (MUC16; CA125)-Directed Immunity Inducers |
Allogenic Cellular Vaccines Autologous Cellular Vaccines Cancer Immunotherapy Cancer Vaccines Polypeptides, from 41 AA Subunit Vaccines |
Cancer, breast |
Elliott-Elliott-Head Breast Cancer (Originator) OncImmune (Originator) |
Phase II | Anti-CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; CD66e) |
Bispecific Antibodies Cancer Immunotherapy Monoclonal Antibodies |
Cancer, thyroid, medullary |
Centre Hospitalier Universitaire Nantes Gilead (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines DNA Vaccines |
Cancer of unspecified body location-system | Medical Marketing Int (d/b/a Oncosense) (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Cancer, breast Cancer, breast, metastatic Cancer, colorectal Cancer, colorectal, metastatic Cancer, lung Cancer, metastatic (to liver) Cancer, pancreas Cancer, solid tumor |
National Cancer Institute Sanofi Pasteur Therion (Originator) |
Phase II | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5; CEA)-Directed Immunity Inducers |
Cancer Immunotherapy Cancer Vaccines Recombinant Vector Vaccines |
Cancer, colorectal Cancer, colorectal, metastatic Immunological Disorders |
National Cancer Institute (Originator) Sanofi Pasteur Therion |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Creative Biolabs is dedicated to advancing antibody research by integrating extensive theoretical knowledge with practical experience, ensuring the delivery of high-quality anti-CEACAM5 antibodies at competitive prices. We invite you to explore our diverse selection of anti-CEACAM5 antibody products and learn how they can support your research objectives. Please don't hesitate to contact us for more information.